139 search results for: Atopic Dermatitis
ADVENT On Air | Exploring PN as a Distinct and Unique Disease
Dr. Sonja Ständer and Dr. Shawn Kwatra discuss the unique features of prurigo nodularis (PN) as well as the characteristics that are shared with atopic dermatitis, and aim to raise awareness of PN among both physicians and patients.
ADVENT at EAPS 2024
The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
Beyond Clinical Control: Targeting Type 2 Inflammation for Improved Patient Outcomes
Prof Alan Irvine presents the latest clinical and real-world evidence supporting the potential for disease modification in atopic dermatitis, at EADV 2025.
Can advanced systemic therapies modify pathomechanisms in AD?
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
ADVENT at San Diego, 2024
Two educational symposia at San Diego, 2024, explore the role of type 2 inflammation and the related manifestations in atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU
Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Both Clinical and Subclinical Disease Control Are Important to Achieve Disease Modification in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.
Global ADVENT FORUM 2023, Dermatology Section | Madrid
New expert presentations from the 2023 ADVENT FORUM, Dermatology section, where the global faculty discuss itch as the common thread in dermatological type 2 inflammation, the evolving concept of disease modification in atopic dermatitis, and the latest updates in prurigo nodularis and chronic spontaneous urticaria.
